Terms: = Ovarian cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A
2246 results:
1. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract] [Full Text] [Related]
2. Ultrasound-based deep learning radiomics model for differentiating benign, borderline, and malignant ovarian tumours: a multi-class classification exploratory study.
Du Y; Guo W; Xiao Y; Chen H; Yao J; Wu J
BMC Med Imaging; 2024 Apr; 24(1):89. PubMed ID: 38622546
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.
Sun W; Xu P; Gao K; Lian W; Sun X
J Cell Mol Med; 2024 Apr; 28(8):e18309. PubMed ID: 38613345
[TBL] [Abstract] [Full Text] [Related]
4. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract] [Full Text] [Related]
5. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
[TBL] [Abstract] [Full Text] [Related]
6. Patient-reported outcome measures (PROMs) to personalise follow-up care of ovarian cancer: what do patients think? A qualitative interview study.
Seeratan DD; van Schuylenburch RG; van Lonkhuijzen LRCW; Aarts JWM
Support Care Cancer; 2024 Mar; 32(4):247. PubMed ID: 38528152
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and immunotherapeutic potential of regulatory T cell-associated signature in ovarian cancer.
Liu Y; Shan F; Sun Y; Kai H; Cao Y; Huang M; Liu J; Zhang P; Zheng Y
J Cell Mol Med; 2024 Apr; 28(8):e18248. PubMed ID: 38520220
[TBL] [Abstract] [Full Text] [Related]
9. Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.
Xiong J; Liang H; Sun X; Gao K
J Cell Mol Med; 2024 Apr; 28(8):e18260. PubMed ID: 38520216
[TBL] [Abstract] [Full Text] [Related]
10. [Preparation and characterization of chicken anti-human B7-H4 IgY polyclonal antibody].
Zhang L; Fan Z; Zhang W; Huang H; Wang J; Hei A; Cong Y; Xu J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):257-266. PubMed ID: 38512036
[TBL] [Abstract] [Full Text] [Related]
11. Identification of prognostic factors and construction of nomogram to predict cancer-specific survival for patients with ovarian granulosa cell tumors.
Zhang Y; Zhang Z; Ding X; Zhang K; Dai Y; Cheng W; Luo C
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2046. PubMed ID: 38507268
[TBL] [Abstract] [Full Text] [Related]
12. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract] [Full Text] [Related]
13. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
Vyhlídalová Kotrbová A; Gömöryová K; Mikulová A; Plešingerová H; Sladeček S; Kravec M; Hrachovinová Š; Potěšil D; Dunsmore G; Blériot C; Bied M; Kotouček J; Bednaříková M; Hausnerová J; Minář L; Crha I; Felsinger M; Zdráhal Z; Ginhoux F; Weinberger V; Bryja V; Pospíchalová V
J Extracell Vesicles; 2024 Mar; 13(3):e12420. PubMed ID: 38490958
[TBL] [Abstract] [Full Text] [Related]
14. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.
Li J; Sun Y; Zhi X; Sun Y; Abudousalamu Z; Lin Q; Li B; Yao L; Chen M
J Ovarian Res; 2024 Mar; 17(1):61. PubMed ID: 38486335
[TBL] [Abstract] [Full Text] [Related]
15. ovarian cancer is detectable from peripheral blood using machine learning over T-cell receptor repertoires.
Zuckerbrot-Schuldenfrei M; Aviel-Ronen S; Zilberberg A; Efroni S
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38483254
[TBL] [Abstract] [Full Text] [Related]
16. Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis.
Wang G; Liu X; You Y; Chen S; Chang X; Yang Q
J Ovarian Res; 2024 Mar; 17(1):58. PubMed ID: 38481252
[TBL] [Abstract] [Full Text] [Related]
17. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract] [Full Text] [Related]
18. Former smoking associated with epigenetic modifications in human granulosa cells among women undergoing assisted reproduction.
Tang Z; Gaskins AJ; Hood RB; Ford JB; Hauser R; Smith AK; Everson TM
Sci Rep; 2024 Feb; 14(1):5009. PubMed ID: 38424222
[TBL] [Abstract] [Full Text] [Related]
19. Computational identification of DNA damage-relevant lncRNAs for predicting therapeutic efficacy and clinical outcomes in cancer.
Liu Y; Huang S; Dong G; Hou C; Zhao Y; Zhang D
Comput Biol Med; 2024 Mar; 171():108107. PubMed ID: 38412692
[TBL] [Abstract] [Full Text] [Related]
20. Assessment of endometrial carcinoma on biopsy as a predictor of final surgical pathology: Are we doing it right? A completed audit cycle and recommendations.
Jassar A; Hemali N; Bhatnagar A
Indian J Pathol Microbiol; 2024; 67(1):68-73. PubMed ID: 38358191
[TBL] [Abstract] [Full Text] [Related]
[Next]
